Sesen Bio, Inc. (SESN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.6183 |
| Open | 0.6101 |
| Bid | 0.5902 x 3200 |
| Ask | 0.5986 x 900 |
| Day's Range | 0.5850 - 0.6240 |
| 52 Week Range | 0.3650 - 0.9650 |
| Volume | |
| Avg. Volume | 1,039,655 |
| Market Cap | 119.668M |
| Beta (5Y Monthly) | 0.86 |
| PE Ratio (TTM) | 1.79 |
| EPS (TTM) | 0.3300 |
| Earnings Date | Feb 27, 2023 - Mar 03, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 0.60 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for SESN
Related Research
- Sesen Bio, Inc.Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.RatingFair ValueEconomic MoatyesterdayMorningstar
- Business Wire
Sesen Bio Receives NASDAQ Delisting Notice
CAMBRIDGE, Mass., January 30, 2023--Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio" or the "Company") today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company’s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the Company’s common stock is subject to delisting.
- Business Wire
Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders
CAMBRIDGE, Mass., January 26, 2023--Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the "Investor Group"):
- Business Wire
Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support
HOUSTON, January 25, 2023--Bradley L. Radoff and Michael Torok (together with their affiliates, the "Investor Group" or "we"), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio"), today issued the following open letter to the Boards of Directors (collectively, the "Boards") of Sesen Bio and Carisma Therapeutics Inc. ("Carisma" and together with Sesen Bio, the "Companies"):
